These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12192774)

  • 41. New developments in coronary stent technology.
    Smith EJ; Jain AK; Rothman MT
    J Interv Cardiol; 2006 Dec; 19(6):493-9. PubMed ID: 17107363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of outcomes of drug-eluting stents versus bare-metal stents in nonostial proximal left anterior descending coronary arteries.
    Bonello L; De Labriolle A; Lemesle G; Roy P; Steinberg DH; Slottow TL; Xue Z; Torguson R; Kaneshige K; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):496-500. PubMed ID: 19195509
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ensuring adequate payment for the use of new technology.
    Kaden RJ
    Healthc Financ Manage; 1998 Feb; 52(2):46-52. PubMed ID: 10176449
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The cost-effectiveness of drug-eluting stents: a systematic review.
    Ligthart S; Vlemmix F; Dendukuri N; Brophy JM
    CMAJ; 2007 Jan; 176(2):199-205. PubMed ID: 17179219
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization.
    Das P; Moliterno DJ; Charnigo R; Mukherjee D; Steinhubl SR; Sneed JD; Booth DC; Ziada KM
    J Invasive Cardiol; 2006 Sep; 18(9):405-8. PubMed ID: 16954577
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Coronary artery aneurysm formation after drug-eluting stent implantation.
    Levisay JP; Roth RM; Schatz RA
    Cardiovasc Revasc Med; 2008; 9(4):284-7. PubMed ID: 18928957
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can we afford to eliminate restenosis? Can we afford not to?
    Greenberg D; Bakhai A; Cohen DJ
    J Am Coll Cardiol; 2004 Feb; 43(4):513-8. PubMed ID: 14975456
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients.
    Halkin A; Selzer F; Marroquin O; Laskey W; Detre K; Cohen H
    J Invasive Cardiol; 2006 Dec; 18(12):577-83. PubMed ID: 17197706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrating new technology without going broke.
    Starr C
    Bus Health; 2002; 20(1):29-34. PubMed ID: 12534112
    [No Abstract]   [Full Text] [Related]  

  • 51. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
    Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
    Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
    Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Securing the inclusion of medical nutrition therapy in managed care health systems.
    Edelman RD; Johnson RK; Coulston AM
    J Am Diet Assoc; 1995 Oct; 95(10):1100-2. PubMed ID: 7560679
    [No Abstract]   [Full Text] [Related]  

  • 54. Are drug eluting stents really worth the money?
    Thomas M
    Heart; 2006 Jan; 92(1):5-7. PubMed ID: 15939723
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Coronary stents: a health system perspective.
    Ahmad M
    Am Heart J; 1999 May; 137(5):S142-4. PubMed ID: 10220618
    [No Abstract]   [Full Text] [Related]  

  • 56. Hospital technology assessment: Part II.
    Rizkalla E
    J Healthc Resour Manag; 1996 May; 14(4):36-8. PubMed ID: 10158189
    [No Abstract]   [Full Text] [Related]  

  • 57. Medical technology at the crossroads.
    Bailey PG
    Adm Radiol; 1987 Nov; 6(11):40-3. PubMed ID: 10312356
    [No Abstract]   [Full Text] [Related]  

  • 58. Has consultants' spigot slowed as providers ponder waste?
    Keener RE
    Health Manag Technol; 2000 Jan; 21(1):10-2. PubMed ID: 10787527
    [No Abstract]   [Full Text] [Related]  

  • 59. The impact of new cardiovascular device technology on health care costs.
    Groeneveld PW; Polsky D; Yang F; Yang L; Epstein AJ
    Arch Intern Med; 2011 Jul; 171(14):1289-91. PubMed ID: 21518936
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacoeconomics and managed care: methodologic and policy issues.
    Luce BR
    Med Decis Making; 1998; 18(2 Suppl):S4-11. PubMed ID: 9566461
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.